GlassScriptPhysician profile
Angela Dee
NPI 1447925128
$4,397.67
in general payments reported to CMS, 2019-2025
34 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $136 · 2023: $1,214 · 2024: $2,043 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198 · Education: $63.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.69 |
| Education | $63.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $646.28 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $433.43 | 2023-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $289.64 | 2023-2025 | |
| Ardelyx, INC. | $199.61 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.06 | 2023-2024 | Trulance |
| Glaxosmithkline, LLC. | $158.62 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $117.60 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $100.44 | 2023-2025 | Dupixent |
| Organon LLC | $94.76 | 2023-2024 | Hadlima, Renflexis |
| Celltrion USA INC. | $90.73 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $81.92 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.42 | 2023-2024 | Cyltezo |
| Qol Medical, LLC | $68.80 | 2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $68.79 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $54.99 | 2022-2023 | Farxiga |
| Madrigal Pharmaceuticals | $54.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $52.37 | 2024 | Rebyota |
| Mallinckrodt Hospital Products INC. | $50.76 | 2024 | Terlivaz |
| Redhill Biopharma INC. | $42.06 | 2023 | Talicia |
| Ironwood Pharmaceuticals, INC | $39.86 | 2023-2024 | Linzess |
| Astellas Pharma US INC | $38.23 | 2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $37.00 | 2022-2023 | |
| Fresenius Kabi USA, LLC | $30.30 | 2023 | Idacio |
| Orphalan INC | $26.96 | 2024 | Cuvrior |
| Amgen INC. | $22.79 | 2025 | Prolia, Evenity |
| Exact Sciences Corporation | $21.53 | 2025 | The Cologuard Plus Collection Kit |
| Biocon Biologics INC | $20.51 | 2025 | Yesintek |
| Genzyme Corporation | $20.01 | 2025 | |
| Mirum Pharmaceuticals, INC. | $18.80 | 2024 | Livmarli |
| Medtronic, INC. | $18.15 | 2025 | Minimed 780g |
| Sandoz INC. | $17.85 | 2023 | Hyrimoz |
| Novo Nordisk INC | $17.39 | 2023 | Ozempic, Rybelsus |
| Braintree Laboratories, INC. | $14.63 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Dee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.